Caredx Stock News

SOUTH SAN FRANCISCO, Calif., Feb. 17, 2022 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients – today announced it will report financial results for the fourth quarter and full year 2021 after market close on Thursday, February 24, 2022. Company management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

SOUTH SAN FRANCISCO, Calif., Feb. 17, 2022 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically dif

More than 100,000 Americans Are on the National Transplant Waiting List and Nearly 20 Die Each Day Waiting for an Organ Transplant They Desperately Need More than 100,000 Americans Are on the National

CareDx Inc (NASDAQ:CDNA)s traded shares stood at 0.39 million during the last session, with the companys beta value hitting 0.67. At the close of trading, the stocks price was $43.20, to imply a decrease of -2.33% or -$1.03 in intraday trading. The CDNA shares 52-week high remains $96.88, putting it -124.26% down since that peak Now Is The Time To Build A Position In CareDx Inc (NASDAQ:CDNA) Read More »

CareDx Supported Education Aims to Reach Underrepresented Minorities with Information on Reducing Cardiovascular Complications Which Can Lead to Kidney Transplant Failure CareDx Supported Education Ai

SOUTH SAN FRANCISCO, Calif., Feb. 03, 2022 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically di

SOUTH SAN FRANCISCO, Calif., Feb. 03, 2022 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically diff

SOUTH SAN FRANCISCO, Calif., Jan. 20, 2022 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically di

CareDx <> said a study showed that AlloSure Kidney is an early and accurate measure of allograft injury in routine organ transplant surveillance and is able to predict

ADMIRAL Study Shows AlloSure Detects Clinical and Subclinical ABMR and TCMR, and Predicts Long-Term Outcomes for Kidney Transplant Patients AlloSure Showed 62% Improvement Over Standard of Care Serum Creatinine SOUTH SAN FRANCISCO, Calif., Jan. 12, 2022 (GLOBE NEWSWIRE) -- CareDx, Inc. (NASDAQ: CDNA ) The Transplant Company focused on the discovery, development, and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients today announced the publication 1 of results from a large, multicenter prospective study showing that AlloSure® Kidney is an early and accurate measure of allograft injury in routine organ transplant surveillance, and is able to predict long-term graft survival outcomes. The ADMIRAL study , Assessing AlloSure Dd-cfDNA Monitoring Insights of Renal Allografts With Longitudinal Surveillance (NCT04566055), monitored 1,092 kidney transplant patients, in a real-world setting, from seven transplant centers for up to three years using the AlloSure Kidney donor-derived cell-free DNA (dd-cfDNA) as part of the standard of care.

The stock price of CareDx, Inc. (Nasdaq: CDNA) increased by 18.48% in the most recent trading session. This is why it happened.

CareDx <> expects prelim Q4 revenue to be in the range of $78.6 to $79M, representing Y/Y growth of 34% to 35%.While the company reported record testing volume and revenues

Caredx Inc (CDNA) shares closed today at 1.7% above its 52 week low of $38.43, giving the company a market cap of $2B. The stock is currently down 14.1% year-to-date, down 51.6% over the past 12 months, and up 1341.2% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 fell 1.9%. Trading Activity Trading volume this week was 11.4% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 2.2. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and beats it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and beats it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and beats it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 84.3% The company's stock price performance over the past 12 months beats the peer average by -8.1% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

ALARM Study Publication Shows Use of AlloSure for Home-Based, Non-invasive Surveillance Monitoring Can Provide a Safer Option for Lung Transplant Recipients Navigating the COVID-19 Pandemic ALARM Stud

SOUTH SAN FRANCISCO, Calif., Jan. 06, 2022 (GLOBE NEWSWIRE) -- CareDx, Inc. (NASDAQ: CDNA ) The Transplant Company focused on the discovery, development, and commercialization of clinically differentiated, healthcare solutions for transplant patients and caregivers today announced the successful completion of the Clinical Laboratory Improvement Amendments (CLIA) validation for AlloMap® Kidney, a blood-based gene expression classifier that identifies immune quiescence, an important biomarker needed to comprehensively assess immunological risk of rejection and allograft health. In clinical validation, published in Kidney360 , AlloMap Kidney demonstrated the ability to differentiate between rejection (both T-cell mediated rejection [TCMR] and antibody-mediated rejection [AMR]) and immune quiescence, and provide an assessment of immunological activity additive to the allograft injury information derived from AlloSure Kidney donor-derived cell-free DNA (dd-cfDNA), with a combined area under the curve (AUC) of 0.894. 1 Together, these two biomarkers offer a more comprehensive assessment of kidney health compared to the current standard of care.